743.73
price up icon0.85%   5.8995
 
loading
前日終値:
$737.83
開ける:
$736.315
24時間の取引高:
1.19M
Relative Volume:
0.28
時価総額:
$703.31B
収益:
$53.26B
当期純損益:
$13.80B
株価収益率:
48.61
EPS:
15.3
ネットキャッシュフロー:
$-50.20M
1週間 パフォーマンス:
+1.66%
1か月 パフォーマンス:
-3.24%
6か月 パフォーマンス:
-18.32%
1年 パフォーマンス:
-21.37%
1日の値動き範囲:
Value
$735.33
$745.52
1週間の範囲:
Value
$723.64
$745.52
52週間の値動き範囲:
Value
$623.78
$943.00

Lilly Eli Co Stock (LLY) Company Profile

Name
名前
Lilly Eli Co
Name
セクター
Healthcare (1154)
Name
電話
(317) 276-2000
Name
住所
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Name
職員
47,000
Name
Twitter
@LillyPad
Name
次回の収益日
2024-10-30
Name
最新のSEC提出書
Name
LLY's Discussions on Twitter

LLY を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - General icon
LLY
Lilly Eli Co
743.10 659.07B 53.26B 13.80B -50.20M 15.30
Drug Manufacturers - General icon
JNJ
Johnson Johnson
177.95 428.83B 90.62B 22.66B 18.18B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
211.74 374.37B 58.33B 3.73B 18.24B 2.10
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
128.65 245.16B 53.40B 13.68B 16.89B 6.9231
Drug Manufacturers - General icon
MRK
Merck Co Inc
83.19 213.51B 63.43B 16.42B 14.72B 6.49

Lilly Eli Co Stock (LLY) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-08-27 アップグレード HSBC Securities Reduce → Hold
2025-08-18 ダウングレード Daiwa Securities Outperform → Neutral
2025-08-07 ダウングレード Leerink Partners Outperform → Market Perform
2025-06-05 ダウングレード Erste Group Buy → Hold
2025-04-28 ダウングレード HSBC Securities Buy → Reduce
2025-04-22 開始されました Cantor Fitzgerald Overweight
2024-12-10 再開されました BofA Securities Buy
2024-11-15 開始されました Wolfe Research Outperform
2024-10-17 開始されました Bernstein Outperform
2024-09-13 再開されました Citigroup Buy
2024-08-12 アップグレード Deutsche Bank Hold → Buy
2024-02-21 ダウングレード DZ Bank Buy → Hold
2024-02-16 繰り返されました Morgan Stanley Overweight
2023-12-21 ダウングレード Daiwa Securities Buy → Outperform
2023-11-09 開始されました Deutsche Bank Hold
2023-10-20 再開されました UBS Buy
2023-08-09 アップグレード Jefferies Hold → Buy
2023-07-26 繰り返されました Citigroup Buy
2023-07-14 開始されました HSBC Securities Buy
2023-05-24 繰り返されました BofA Securities Buy
2023-05-24 繰り返されました UBS Buy
2023-03-13 アップグレード Wells Fargo Equal Weight → Overweight
2023-03-06 開始されました Jefferies Hold
2023-02-15 ダウングレード Societe Generale Hold → Sell
2022-11-18 開始されました Credit Suisse Outperform
2022-09-22 アップグレード UBS Neutral → Buy
2022-05-23 開始されました SVB Leerink Outperform
2022-04-06 再開されました Morgan Stanley Overweight
2022-03-10 開始されました Daiwa Securities Outperform
2022-01-21 アップグレード DZ Bank Hold → Buy
2022-01-03 繰り返されました Bernstein Mkt Perform
2021-12-17 開始されました Goldman Neutral
2021-12-16 繰り返されました BMO Capital Markets Outperform
2021-12-16 繰り返されました BofA Securities Buy
2021-12-09 再開されました Wells Fargo Equal Weight
2021-11-19 開始されました BMO Capital Markets Outperform
2021-10-11 アップグレード Berenberg Hold → Buy
2021-09-29 アップグレード Citigroup Neutral → Buy
2021-08-05 アップグレード DZ Bank Hold → Buy
2021-07-27 再開されました Truist Buy
2021-06-24 繰り返されました Cantor Fitzgerald Overweight
2021-01-19 アップグレード Mizuho Neutral → Buy
2020-12-10 アップグレード Wolfe Research Peer Perform → Outperform
2020-11-10 再開されました Bernstein Mkt Perform
2020-09-29 開始されました Berenberg Hold
2020-09-03 アップグレード Morgan Stanley Equal-Weight → Overweight
2020-06-16 アップグレード Guggenheim Neutral → Buy
2020-04-21 ダウングレード UBS Buy → Neutral
2020-04-09 ダウングレード Morgan Stanley Overweight → Equal-Weight
2020-02-06 開始されました Mizuho Neutral
2019-12-18 アップグレード Morgan Stanley Equal-Weight → Overweight
2019-10-17 再開されました BofA/Merrill Buy
2019-05-28 開始されました Goldman Buy
2019-04-24 アップグレード Edward Jones Hold → Buy
2019-04-11 ダウングレード Guggenheim Buy → Neutral
2019-03-12 開始されました JP Morgan Overweight
2019-01-23 開始されました UBS Buy
2018-11-26 ダウングレード Citigroup Buy → Neutral
2018-10-31 アップグレード Credit Suisse Underperform → Neutral
2018-10-09 開始されました Guggenheim Buy
2018-10-01 繰り返されました SunTrust Buy
2018-09-26 再開されました JP Morgan Overweight
すべてを表示

Lilly Eli Co (LLY) 最新ニュース

pulisher
Sep 03, 2025

Hims & Hers gains after court rejects Eli Lilly’s case against Willow - Yahoo Finance

Sep 03, 2025
pulisher
Sep 03, 2025

BMO Capital Markets Reaffirms ‘Buy Rating’ on Eli Lilly Stock (LLY) - TipRanks

Sep 03, 2025
pulisher
Sep 03, 2025

Gastric Cancer Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Eli Lilly and Company, BeiGene, Hutchison MediPharma, Astellas Pharma, Henlix - Barchart.com

Sep 03, 2025
pulisher
Sep 03, 2025

PRESSR: Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity - TradingView

Sep 03, 2025
pulisher
Sep 03, 2025

Is Novo Nordisk Stock a Buy Now? - The Motley Fool

Sep 03, 2025
pulisher
Sep 03, 2025

Stomach Cancer Treatment Market Review 2020-2024 and Forecast 2025-2030 - GlobeNewswire Inc.

Sep 03, 2025
pulisher
Sep 02, 2025

Fueled by Lilly's Lebanon investment, local builds future in biotech at Ivy Tech - reporter.net

Sep 02, 2025
pulisher
Sep 02, 2025

Analyst Forecasts $25 Billion of Annual Sales for Eli Lilly’s (LLY) New Weight-Loss Pill - TipRanks

Sep 02, 2025
pulisher
Sep 02, 2025

Eli Lilly's once-daily obesity pill passes phase 3 trials - 조선일보

Sep 02, 2025
pulisher
Sep 02, 2025

BMO Capital Affirms Eli Lilly (LLY)’s ‘Outperform’ Rating on Weight Loss Drug Prospects - Yahoo Finance

Sep 02, 2025
pulisher
Sep 02, 2025

Eli Lilly's New Drugs Beyond Mounjaro And Zepbound Boost Sales - Barchart.com

Sep 02, 2025
pulisher
Sep 02, 2025

Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales - Nasdaq

Sep 02, 2025
pulisher
Sep 02, 2025

What's Going On With Novo Nordisk Stock Tuesday?Novo Nordisk (NYSE:NVO), Eli Lilly (NYSE:LLY) - Benzinga

Sep 02, 2025
pulisher
Sep 02, 2025

Eyes on Asia: Lilly, Fosun, RemeGene - BioXconomy

Sep 02, 2025
pulisher
Sep 02, 2025

Lilly Ends Two Mid-Stage Trials for Second Obesity Asset - BioSpace

Sep 02, 2025
pulisher
Sep 02, 2025

Is Eli Lilly and Company’s growth already priced inJuly 2025 Decliners & Fast Moving Stock Watchlists - خودرو بانک

Sep 02, 2025
pulisher
Sep 02, 2025

Eli Lilly & Co: Strong Buy Rating Driven by Promising Weight Loss Drug and Innovative Subscription Model - TipRanks

Sep 02, 2025
pulisher
Sep 02, 2025

Recently, Eli Lilly's obesity treatment "Munzaro" has been released in Korea and interest in obesity.. - 매일경제

Sep 02, 2025
pulisher
Sep 02, 2025

Recently, Eli Lilly's obesity treatment Maunzaro was released in Korea, and as interest in obesity t.. - 매일경제

Sep 02, 2025
pulisher
Sep 02, 2025

Eli Lilly and Company (LLY) Halts UK Mounjaro Shipments Ahead of Planned Price Increase - uk.finance.yahoo.com

Sep 02, 2025
pulisher
Sep 01, 2025

Can trapped investors hope for a rebound in Eli Lilly and CompanyTrade Performance Summary & Detailed Earnings Play Alerts - Newser

Sep 01, 2025
pulisher
Sep 01, 2025

Eli Lilly’s SWOT analysis: stock’s growth potential in obesity market faces challenges - Investing.com

Sep 01, 2025
pulisher
Sep 01, 2025

Eli Lilly (LLY) Partners with JD.com to Sell Weight-Loss Drugs in China - TipRanks

Sep 01, 2025
pulisher
Sep 01, 2025

ESC25: Novo's Wegovy slashes CV risk by 57% over Lilly's Zepbound in real-world study - FirstWord Pharma

Sep 01, 2025
pulisher
Sep 01, 2025

Novo Nordisk Says Wegovy Cuts Heart Risk by 57% Compared With Eli Lilly’s Obesity Drug - The Wall Street Journal

Sep 01, 2025
pulisher
Aug 31, 2025

Eli Lilly and Company Stock (LLY) Opinions on Orforglipron Trial Data | LLY Stock News - Quiver Quantitative

Aug 31, 2025
pulisher
Aug 31, 2025

Can you recover from losses in Eli Lilly and CompanyJuly 2025 Levels & Verified Chart Pattern Trade Signals - Newser

Aug 31, 2025
pulisher
Aug 31, 2025

HSBC Upgrades Eli Lilly (LLY) to Hold, Lifts Price Target to $700 - Yahoo Finance

Aug 31, 2025
pulisher
Aug 30, 2025

Intraday pattern recognizer results for Eli Lilly and CompanyPortfolio Risk Report & Fast Exit Strategy with Risk Control - Newser

Aug 30, 2025
pulisher
Aug 30, 2025

Benzinga Bulls And Bears: Eli Lilly, Firefly, Marvell — And Trump Investment Hints Boost Defense Stocks - inkl

Aug 30, 2025
pulisher
Aug 30, 2025

Eli Lilly is close to launching the strongest weight-loss drug ever. Somehow, gym bros are already taking it to shred fat. - Business Insider

Aug 30, 2025
pulisher
Aug 30, 2025

Eli Lilly and Company (LLY): A Bull Case Theory - MSN

Aug 30, 2025
pulisher
Aug 29, 2025

Sector ETF performance correlation with Eli Lilly and Company2025 Geopolitical Influence & Consistent Profit Trading Strategies - Newser

Aug 29, 2025
pulisher
Aug 29, 2025

Eli Lilly and Company (LLY) Needs To Get A Weight Loss Pill Out, Says Jim Cramer - Yahoo Finance

Aug 29, 2025
pulisher
Aug 29, 2025

Pharmaceutical Cos. Back Lilly In Mich. Insulin Pricing Probe - Law360

Aug 29, 2025
pulisher
Aug 29, 2025

Jim Cramer Sees Big Potential in Eli Lilly’s Weight-Loss and Diabetes Pill - Yahoo Finance

Aug 29, 2025
pulisher
Aug 29, 2025

The Zacks Analyst Blog Highlights Lilly, Oracle, Procter & Gamble and Comstock Holding Companies - ca.finance.yahoo.com

Aug 29, 2025
pulisher
Aug 29, 2025

Eli Lilly (NYSE:LLY) vs Novo Nordisk (NYSE:NVO): Growth Premium vs Value Upside - tradingnews.com

Aug 29, 2025
pulisher
Aug 29, 2025

Eli Lilly (NYSE:LLY) Stock Price Trading at $732 as GLP-1 Sales Surge and Drug Pricing Risks Rise - tradingnews.com

Aug 29, 2025
pulisher
Aug 29, 2025

Is Eli Lilly Stock A Buy As The Company Aims For Weight-Loss Pill Approval? - Investor's Business Daily

Aug 29, 2025
pulisher
Aug 29, 2025

Eli Lilly Stock: Is LLY Underperforming the Healthcare Sector? - Yahoo Finance

Aug 29, 2025
pulisher
Aug 29, 2025

Eli Lilly Temporarily Stops U.K. Shipments of Its Weight-Loss Drug - TipRanks

Aug 29, 2025
pulisher
Aug 29, 2025

Eli Lilly Partners with JD Health for Direct-to-Consumer Obesity and Diabetes Drug Sales - AInvest

Aug 29, 2025
pulisher
Aug 29, 2025

JD Health (06618.HK) has reached a strategic cooperation agreement with Eli Lilly and Co in China. - 富途牛牛

Aug 29, 2025
pulisher
Aug 29, 2025

LLY Stock Quote Price and Forecast - CNN

Aug 29, 2025
pulisher
Aug 29, 2025

Eli Lilly Partners With China Tech Giant for Obesity Drug Sales - Bloomberg

Aug 29, 2025
pulisher
Aug 29, 2025

Eli Lilly to offer UK discount on Mounjaro weight-loss jabs - The Independent

Aug 29, 2025
pulisher
Aug 28, 2025

Decoding Insider Activity at Eli Lilly: A Closer Look at Recent Share Sales and Buying Conviction - AInvest

Aug 28, 2025
pulisher
Aug 28, 2025

Top Stock Reports for Eli Lilly, Oracle & Procter & Gamble - Nasdaq

Aug 28, 2025
pulisher
Aug 28, 2025

Eli Lilly CIO Susan Ridlen retiring - Pensions & Investments

Aug 28, 2025
pulisher
Aug 28, 2025

Eli Lilly (LLY) technical analysisEli Lilly (NYSE:LLY) - Benzinga

Aug 28, 2025

Lilly Eli Co (LLY) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
drug_manufacturers_general JNJ
$177.87
price down icon 0.08%
$211.88
price down icon 0.02%
drug_manufacturers_general NVS
$128.64
price up icon 0.33%
drug_manufacturers_general MRK
$83.24
price down icon 1.09%
drug_manufacturers_general NVO
$56.39
price down icon 0.52%
大文字化:     |  ボリューム (24 時間):